BridgeBio Pharma, Inc. Intellectual Property Contracts & Agreements
7 Contracts & Agreements
- License Agreements (7 contracts)
- Letter Agreement, Amendment #1 thereto, and Amendments to License Agreement between QED Therapeutics, Inc. and Novartis International Pharmaceutical Ltd., dated May 4, 2018,... (Filed With SEC on February 22, 2024)
- Fourth Amendment to the Exclusive License Agreement, between The Regents of the University of California and TheRas, Inc., dated December 16, 2019 (Filed With SEC on March 3, 2020)
- License Agreement, by and between the Registrant and Alexion Pharma International Operations Unlimited Company, dated September 9, 2019 (Filed With SEC on November 8, 2019)
- Cell Line License Agreement, by and between Life Technologies Corporation and BridgeBio Services, Inc., effective as of November 15, 2018 (Filed With SEC on May 24, 2019)
- Exclusive Patent License Agreement, between The Frederick National Laboratory for Cancer Research, operated by Leidos Biomedical Research, Inc., under sponsorship from the... (Filed With SEC on May 24, 2019)
- Exclusive License Agreement, between The Regents of the University of California and TheRas, Inc., dated September 28, 2016, as amended by First Amendment effective January 10,... (Filed With SEC on May 24, 2019)
- License Agreement, between QED Therapeutics, Inc. and Novartis International Pharmaceutical Ltd., dated as of January 29, 2018 (Filed With SEC on May 24, 2019)
